Early triple negative breast cancer
Conditions
Brief summary
pCR with the addition of capecitabine compared with carboplatin-based chemotherapy alone.
Detailed description
Invasive Disease Survival (IDFS) with the addition of capecitabine compared with carboplatin-based chemotherapy alone., Breast Cancer Specific Survival (BCSS) with the addition of capecitabine compared with carboplatin-based chemotherapy alone., Overall Survival (OS) with the addition of capecitabine compared with carboplatin-based chemotherapy alone.
Interventions
DRUGCAPECITABINE
DRUGPACLITAXEL
DRUGKEYTRUDA 25 mg/mL concentrate for solution for infusion
DRUGEPIRUBICIN
DRUGCYCLOPHOSPHAMIDE
DRUGCARBOPLATIN
Sponsors
Region Skåne
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| pCR with the addition of capecitabine compared with carboplatin-based chemotherapy alone. | — |
Secondary
| Measure | Time frame |
|---|---|
| Invasive Disease Survival (IDFS) with the addition of capecitabine compared with carboplatin-based chemotherapy alone., Breast Cancer Specific Survival (BCSS) with the addition of capecitabine compared with carboplatin-based chemotherapy alone., Overall Survival (OS) with the addition of capecitabine compared with carboplatin-based chemotherapy alone. | — |
Countries
Denmark, Sweden
Outcome results
None listed